Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics director Roy D. Baynes exercised stock options and sold the resulting shares in a pre-planned transaction. On May 5, he exercised options for 4,500 shares of common stock at $18.27 per share and sold 4,500 shares at $46.65 per share in an open-market sale. The sale was made under a written Rule 10b5-1(c) trading plan adopted on November 17, 2025 and involved fully vested, exercisable options. After these transactions, Baynes directly owns 37,500 shares of Travere Therapeutics common stock, with no remaining position from the exercised options.
Travere Therapeutics director Jeffrey A. Meckler exercised stock options for 8,000 shares of common stock at $16.33 per share, then sold 8,000 shares at $45.00 per share in an open‑market transaction. The sale was made under a pre‑arranged Rule 10b5‑1(c) trading plan. Following these transactions, Meckler directly owns 87,500 shares of Travere Therapeutics common stock.
Travere Therapeutics Chief Research Officer William E. Rote reported a mix of equity award activity and a small share sale. On May 4, 2026, 4,250 performance-based restricted stock units converted into common stock after a cumulative FILSPARI net revenue performance criterion was met, and he received a new grant of 8,500 performance-based units. The filing notes that an additional 25% of these units is scheduled to vest on January 31, 2027, contingent on continued service. On May 6, 2026, he sold 2,763 shares of common stock at $43.95 per share under a pre-arranged Rule 10b5-1 trading plan that also covered tax obligations from the vesting. Following the transactions, he directly holds 115,474 common shares.
Travere Therapeutics, Inc. Chief Legal Officer and General Counsel Elizabeth E. Reed reported a mix of option exercises, PSU activity and share sales. On May 4, 2026 she exercised employee stock options and performance-based restricted stock units covering a total of 24,250 shares of common stock, including 20,000 options at a $17.96 exercise price.
That same day, she sold 20,000 shares at $45.00 per share, and on May 5 and 6, 2026 she sold additional blocks of 2,174 shares at $46.65 and 2,076 shares at $43.95. Footnotes state that certain sales were made under a Rule 10b5‑1 trading plan and that some shares were sold to cover tax withholding obligations related to vested performance-based RSUs, rather than as discretionary trades. After these transactions, she directly held 105,211 shares of Travere common stock and performance-based restricted stock units covering 8,500 shares at target.
Travere Therapeutics Chief Medical Officer Jula Inrig reported a combination of equity award activity and stock sales. On May 4, 2026, she exercised 20,000 employee stock options with a $22.40 exercise price and sold 20,000 shares of common stock at $45.00 per share, alongside the vesting and conversion of 4,250 performance-based restricted stock units (PSUs) into common stock.
On May 5 and 6, 2026, she sold additional blocks of 2,174 and 311 shares at $46.65 and $43.95 per share. Footnotes state that certain sales, including tax “sell to cover” transactions, were conducted under a pre-arranged Rule 10b5-1 trading plan rather than as fully discretionary trades. Following these transactions, Inrig directly holds 113,238 shares of common stock, plus 34,500 stock options and 8,500 PSUs subject to future vesting conditions.
Travere Therapeutics’ chief commercial officer Peter Heerma reported a mix of equity award vesting and a required tax-related sale. On May 4, 2026, 4,250 performance-based restricted stock units (PSUs) vested, converting into 4,250 shares of common stock after Travere confirmed a FILSPARI cumulative net revenue performance milestone tied to results for the quarter ended March 31, 2026.
Those PSUs are part of an 8,500-unit grant awarded on January 31, 2024, with an additional 25% scheduled to vest on January 31, 2027, contingent on continued service. The filing notes that up to 50% additional shares could vest later if certain milestones are achieved on an accelerated timeline. On May 5, 2026, Heerma sold 2,174 shares at $46.65 per share to cover tax withholding obligations under a mandatory “sell to cover” arrangement chosen by the company, described as a non-discretionary sale. After these transactions, he directly holds 140,684 shares of Travere common stock.
Travere Therapeutics CEO Eric M. Dube exercised performance-based restricted stock units and sold shares in a planned, routine transaction. On May 6, 2026, he sold 22,500 shares of common stock at $43.95 per share in an open-market trade under a pre-arranged Rule 10b5-1(c) plan that also covered tax obligations from vesting.
Two days earlier, on May 4, 2026, he exercised 22,500 performance-based restricted stock units into common shares and received a new grant covering 45,000 PSUs. The filing states 50% of these PSUs vested after a cumulative FILSPARI net revenue performance target was confirmed, with an additional 25% scheduled to vest on January 31, 2027 if he remains in continuous service.
After these transactions, Dube directly holds 432,886 shares of Travere Therapeutics common stock, indicating he retains a substantial equity stake.
Travere Therapeutics’ CFO Christopher R. Cline reported a mix of equity awards, vesting and share sales. On May 4, 2026, he exercised performance-based restricted stock units (PSUs) covering 4,250 shares of common stock at a conversion price of $0.00 per share, following the vesting of 50% of PSUs originally granted on January 31, 2024. Those PSUs vested after the company confirmed that a performance criterion tied to cumulative FILSPARI net revenue for the quarter ended March 31, 2026 had been achieved. The same grant allows up to 50% additional shares to vest on an accelerated timeline and provides that a further 25% will vest on January 31, 2027, contingent on continued service.
Also on May 4, 2026, he received a new grant of 8,500 PSUs, each representing a contingent right to one share of common stock at target, subject to performance adjustments. On May 5 and May 6, 2026, he sold a total of 2,491 shares of common stock at prices of $46.65 and $43.95 per share. According to the footnotes, these sales were executed under a written Rule 10b5-1(c) trading plan adopted on May 28, 2025 and include shares sold to cover tax withholding obligations arising from PSU vesting. After these transactions, he directly owned 118,658 shares of Travere Therapeutics common stock.
Travere Therapeutics, Inc. officer Christopher Cline reported a planned sale of 310 common shares, with an aggregate market value of $13,624.50 and an approximate sale date of May 6, 2026.
The notice lists 310 performance shares acquired from the issuer on May 4, 2026, and gives May 28, 2025 as the Rule 10b5-1 plan adoption or instruction date. It also lists five prior sales from April 13 through May 5, 2026, including 2,181 shares sold on May 5 for gross proceeds of $101,743.65.
Travere Therapeutics, Inc. officer Elizabeth Reed reported a proposed sale of 2,076 common shares, with an aggregate market value of $91,240.20 and an approximate sale date of May 6, 2026. She also reported acquiring 2,076 performance shares from the issuer on May 4, 2026. Common shares outstanding were listed at 92,992,905. The Rule 10b5-1 plan adoption or instruction date is June 16, 2025. Reed’s other reported common-share sales were dated February 17, 2026, through May 5, 2026.